PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...

together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...

The study was funded by Janssen Oncology. Access disclosures for Dr. Yu. Only patients with persistent EGFR in circulating tumor DNA (ctDNA) after initiating therapy with osimertinib are randomized to ...

Per independent review, the median progression-free survival was 7.5 months. Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant non ...

The decision was welcomed by patient organisation EGFR Positive, whose co-chair – Jenny Abbott – said: “Osimertinib is an important treatment option for these patients, with the potential to ...

Researchers conducted an exploratory analysis of 220 patients from ADAURA, including 112 who received osimertinib and 108 who received placebo. MRD was assessed using tumour-informed circulating ...

A NEW post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).

Final overall survival data from the MARIPOSA trial show that amivantamab and lazertinib improves survival vs osimertinib in EGFR-mutated NSCLC. Amivantamab-vmjw data (Rybrevant) plus lazertinib ...

--(BUSINESS WIRE)--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO ® (osimertinib), as monotherapy and as ...